Related Experiment Video
Updated: Oct 23, 2025

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography
Published on: September 22, 2011
Glypican 1 and syndecan 1 differently regulate noradrenergic hypertension development: Focus on IP3R and calcium
Simone R Potje1, Ayman Isbatan2, Rita C Tostes3
1Department of Anesthesiology, College of Medicine Tucson, University of Arizona, USA; Department of Anesthesiology, College of Medicine, University of Illinois at Chicago, USA; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil; Department of Physics and Chemistry, Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
Insights
Glypican 1 and syndecan 1 regulate blood pressure. Glypican 1 deficiency protects against hypertension by altering calcium signaling, suggesting it as a therapeutic target.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Hypertension Research
Background:
- Vascular dysfunction is critical in hypertension development.
- Heparan sulfate proteoglycans (HSPG) influence nitric oxide (NO) and calcium signaling, vital for vascular function.
- The roles of HSPG in NO/calcium signaling, vascular dysfunction, and blood pressure regulation remain unclear.
Purpose of the Study:
- To investigate if HSPGs, specifically syndecan 1 and glypican 1, control systemic blood pressure.
- To elucidate the mechanisms by which glypican 1 and syndecan 1 regulate vascular tone.
- To determine their contribution to the development of noradrenergic hypertension.
Main Methods:
- Systemic arterial blood pressure assessment in knockout mouse models (Sdc1-/- and Gpc1-/-).
- Evaluation of calcium-dependent vasoconstriction and expression of calcium-sensitive proteins.
- Analysis of inositol trisphosphate receptor (IP3R) activity and endoplasmic reticulum calcium storage.
Main Results:
- Both Sdc1-/- and Gpc1-/- mice exhibited decreased systolic blood pressure, notably in Gpc1-/-.
- Gpc1-/- mice were protected from norepinephrine-induced hypertension.
- This protection correlated with impaired calcium-dependent vasoconstriction, altered SERCA and calmodulin expression, reduced IP3R activity, and increased ER calcium storage in Gpc1-/- mice.
Conclusions:
- Glypican 1 acts as a trigger for noradrenergic hypertension via IP3R and calcium signaling pathways.
- Glypican 1 represents a potential therapeutic target for resistant hypertension.
- Targeting Glypican 1 may offer new treatment strategies for conditions with elevated norepinephrine.
Background:
Vascular dysfunction is a checkpoint to the development of hypertension. Heparan sulfate proteoglycans (HSPG) participate in nitric oxide (NO) and calcium signaling, key regulators of vascular function. The relationship between HSPG-mediated NO and calcium signaling and vascular dysfunction has not been explored. Likewise, the role of HSPG on the control of systemic blood arterial pressure is unknown. Herein, we sought to determine if the HSPG syndecan 1 and glypican 1 control systemic blood pressure and the progression of hypertension.
Purpose:
To determine the mechanisms whereby glypican 1 and syndecan 1 regulate vascular tone and contribute to the development of noradrenergic hypertension.
Experimental Approach And Key Results:
By assessing systemic arterial blood pressure we observed that syndecan 1 (Sdc1-/-) and glypican 1 (Gpc1-/-) knockout mice show a similar phenotype of decreased systolic blood pressure that is presented in a striking manner in the Gpc1-/- strain. Gpc1-/- mice are also uniquely protected from a norepinephrine hypertensive challenge failing to become hypertensive. This phenotype was associated with impaired calcium-dependent vasoconstriction and altered expression of calcium-sensitive proteins including SERCA and calmodulin. In addition, Gpc1-/- distinctively showed decreased IP3R activity and increased calcium storage in the endoplasmic reticulum.
Conclusions And Implications:
Glypican 1 is a trigger for the development of noradrenergic hypertension that acts via IP3R- and calcium-dependent signaling pathways. Glypican 1 may be a potential target for the development of new therapies for resistant hypertension or conditions where norepinephrine levels are increased.
More Related Videos
08:08Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta
Published on: June 10, 2015
08:46Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
Published on: September 1, 2015
Related Concept Videos
GPCRs Regulate Adenylyl Cylase Activity
IP3/DAG Signaling Pathway
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Nitric Oxide Signaling Pathway
GPCR Desensitization
Neural Regulation of Blood Pressure
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...